C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.
C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.
复制标题
C 反应蛋白水平可预测肝细胞癌患者对 PD-1 抑制剂的反应
DOI：
10.3389/fimmu.2022.808101
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
Cai MY
中科院分区：
文献类型：
--
作者：
Zhang Y;Lu L;He Z;Xu Z;Xiang Z;Nie RC;Lin W;Chen W;Zhou J;Yin Y;Xie J;Zhang Y;Zheng X;Zhu T;Cai X;Li P;Chao X;Cai MY
Background Serum C-reactive protein (CRP) is a biomarker of an acute inflammatory response and has been successfully used as a prognostic predictor for several malignancies. However, the clinicopathological significance of CRP levels in hepatocellular carcinoma (HCC) patients being treated with PD-1 inhibitors remains unclear. Methods Serum CRP levels were measured for a total of 101 HCC patients that had been treated with PD-1 inhibitors from July 2018 to November 2019. The clinicopathological data was retrospectively analyzed to identify any clinical implications between CRP levels and responses to PD-1 inhibitors and patients’ progression-free survival (PFS). Results The median PFS was 8.87 months in the CRP-low subgroup and 3.67 months in the CRP-high subgroup (P = 0.009). Univariate and multivariate Cox regression analysis demonstrated that both serum CRP and AFP levels were independent risk factors for the PFS of HCC patients treated with PD-1 inhibitors (P < 0.05). Moreover, Cox regression analysis after Propensity Score Matching showed the similar results. A prognostic model combining CRP and AFP levels could significantly stratify HCC patients receiving PD-1 inhibitors into low-, intermediate-, and high-risk subgroups (P < 0.001). Patients in the risk subgroups reported similar overall response rates (P = 0.625) and significantly different disease control rates (low- vs. intermediate- vs. high-risk groups: 81.6% vs. 65.1% vs. 35%, respectively, P = 0.002). Conclusions The results of this study support the association between high serum CRP levels with the response and PFS for HCC patients receiving PD-1 inhibitors. Furthermore, the levels of both CRP and AFP in an HCC patient before treatment initiation show great potential for determining the efficacy of PD-1 inhibitors.
登录
查看更多内容
影响因子：
7.3
作者：
Jimenez RV;Wright TT;Jones NR;Wu J;Gibson AW;Szalai AJ
通讯作者：
Szalai AJ
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
DOI：
10.1038/s41577-019-0218-4
发表时间：
2020-01
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Kalbasi A;Ribas A
通讯作者：
Ribas A
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
对肝细胞癌 PD-1 抑制有反应和无反应患者的临床和遗传肿瘤特征。
影响因子：
5.2
作者：
Spahn S;Roessler D;Pompilia R;Gabernet G;Gladstone BP;Horger M;Biskup S;Feldhahn M;Nahnsen S;Hilke FJ;Scheiner B;Dufour JF;De Toni EN;Pinter M;Malek NP;Bitzer M
通讯作者：
Bitzer M